The UK’s medicines regulator has authorized a new immunotherapy for adults living with advanced Merkel cell carcinoma (MCC), marking the first approved treatment specifically for patients whose disease has spread or returned and can no longer be treated successfully with surgery or radiotherapy.
New Treatment Option Cleared for Advanced Disease
The Medicines and Healthcare products Regulatory Agency (MHRA) announced on 6 July 2026 that it has approved Retifanlimab (ZYNYZ) for adults with advanced Merkel cell carcinoma whose cancer is either metastatic or recurrent and is not curable through surgical intervention or radiation therapy.
The decision provides a long-awaited treatment option for patients diagnosed with one of the rarest and most aggressive forms of skin cancer, expanding therapeutic choices for individuals with limited alternatives.
Understanding Merkel Cell Carcinoma
Merkel cell carcinoma is an uncommon but highly aggressive skin cancer that develops from Merkel cells—specialized neuroendocrine cells located in the upper layer of the skin.
Although rare, the disease is known for its rapid progression and its tendency to spread to other parts of the body, making effective treatment particularly challenging once it reaches an advanced stage.
How Retifanlimab Works
Retifanlimab is an immunotherapy designed to strengthen the body’s natural immune response against cancer.
The medicine works by blocking a biological pathway that tumors often exploit to evade immune detection.
By preventing cancer cells from hiding from the immune system, the treatment enables immune cells to recognize and attack malignant cells more effectively.
Patients receive the medicine through a diluted intravenous infusion administered over approximately 30 minutes.
Clinical Trial Results Show Encouraging Outcomes
The MHRA’s approval was supported by findings from a clinical study involving 101 adults with advanced Merkel cell carcinoma who had not previously received systemic treatment for their advanced disease.
More than half of the participants—53.5%—experienced a measurable response after receiving Retifanlimab.
Among those patients, 16.8% achieved a complete response, meaning no detectable signs of cancer remained following treatment.
Another 36.6% experienced partial responses, with significant reductions in tumor size.
For patients who responded to therapy, the treatment effect typically lasted slightly longer than two years, highlighting the potential for durable disease control.
MHRA Highlights Significance of Approval
Commenting on the authorization, Julian Beach, Executive Director of Healthcare Quality and Access at the MHRA, described the approval as an important milestone for people living with advanced Merkel cell carcinoma.
He noted that the decision introduces the first approved treatment for adults whose cancer has spread or returned and cannot be cured through surgery or radiotherapy.
Beach also emphasized that the regulator will continue monitoring the medicine’s safety and effectiveness as its use expands in clinical practice.
Safety Monitoring Will Continue
As with all newly approved medicines, Retifanlimab will remain subject to ongoing pharmacovigilance.
Healthcare professionals and patients are encouraged to report any suspected adverse reactions, allowing regulators to continually evaluate the medicine’s benefit-risk profile.
The complete list of known side effects is available in the Patient Information Leaflet and the Summary of Product Characteristics, which will be published on the MHRA’s products website.
Approval Details
The authorization was granted on 6 July 2026 to Incyte Biosciences UK Ltd through the International Recognition Procedure (IRP), a regulatory pathway used by the MHRA to assess eligible medicines.
Updated prescribing information, including the Summary of Product Characteristics and Patient Information Leaflet, is expected to be published within seven days of the approval.
MHRA’s Regulatory Role
The Medicines and Healthcare products Regulatory Agency is responsible for ensuring that medicines and medical devices available in the United Kingdom meet appropriate standards of quality, safety, and effectiveness.
Operating as an executive agency of the Department of Health and Social Care, the MHRA evaluates evidence to ensure that the benefits of approved products outweigh any potential risks before they reach patients.
